Administering IMP

[MHRA Moderator]

While the response would be the ideal situation and may be appropriate for certain methods of administration (i.e. iv administration of chemotherapy) patients can also self-administer in clincial trials. Therefore, when considering the risk assessemnt of the clincial trial, considerations should be given to who can administer the IMP. If it is a simple tablet for example, it may be that someone that is not medically qualified can administer this, provided they a suitably trained in the protocol and dosing activity (they could not make the decision to prescribe though, this must be a suitably qualified medic).